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ABSTRACT
Objective: Although regulatory authorities evaluate the risks and beneﬁts
of any new drug therapy during the new drug-approval process, quanti-
tative risk–beneﬁt assessment (RBA) is not typically performed, nor is it
presented in a consistent and integrated framework when it is used. Our
purpose is to identify and describe published quantitative RBA methods
for pharmaceuticals.
Methods: Using MEDLINE and other Internet-based search engines, a
systematic literature review was performed to identify quantitative meth-
odologies for RBA. These distinct RBA approaches were summarized to
highlight the implications of their differences for the pharmaceutical
industry and regulatory agencies.
Results: Theoretical models, parameters, and key features were reviewed
and compared for the 12 quantitative RBA methods identiﬁed in the
literature, including the Quantitative Framework for Risk and Beneﬁt
Assessment, beneﬁt-less-risk analysis, the quality-adjusted time without
symptoms and toxicity, number needed to treat (NNT), and number
needed to harm and their relative-value-adjusted versions, minimum clini-
cal efﬁcacy, incremental net health beneﬁt, the risk–beneﬁt plane (RBP),
the probabilistic simulation method, multicriteria decision analysis
(MCDA), the risk–beneﬁt contour (RBC), and the stated preference
method (SPM). Whereas some approaches (e.g., NNT) rely on subjective
weighting schemes or nonstatistical assessments, other methods (e.g., RBP,
MCDA, RBC, and SPM) assess joint distributions of beneﬁt and risk.
Conclusions: Several quantitative RBA methods are available that could
be used to help lessen concern over subjective drug assessments and to help
guide authorities toward more objective and transparent decision-making.
When evaluating a new drug therapy, we recommend the use of multiple
RBA approaches across different therapeutic indications and treatment
populations in order to bound the risk–beneﬁt proﬁle.
Keywords: drug safety, incremental risk–beneﬁt ratio, multicriteria deci-
sion analysis, number needed to treat, risk–beneﬁt assessment, risk–beneﬁt
plane, stated preference method.
Introduction
In the past decade, over a dozen high-proﬁle brand-name drugs,
including rofecoxib, troglitazone, cisapride, and cerivastatin,
were withdrawn from the market [1]. The US Food and Drug
Administration (FDA) established a Drug Safety and Risk Man-
agement Division, which is charged with evaluating the safety,
efﬁcacy, and abuse potential of drugs, as well as risk management
and risk communication. In March 2005, the FDA issued risk
management guidance for the pharmaceutical industry, which
included three separate guidelines: Premarketing Risk Assess-
ment, Development and Use of Risk Minimization Action Plans,
and Good Pharmacovigilance Practices and Pharmacoepidemio-
logic Assessment [2–5]. In 2007, Title IX of the FDA Amend-
ments Act gave the FDA the authority to require companies to
develop and implement a risk evaluation and mitigation strategy
for speciﬁed prescription drugs. In this era of renewed focus on
drug safety, the FDA has called for more creative approaches to
conceptualizing, measuring, and applying risk–beneﬁt assess-
ment (RBA) techniques to develop and improve a systematic
RBA approach throughout the life cycle of a pharmaceutical
product [6–9]. Appropriate RBA can provide useful information
for proactive intervention in health-care settings, which could
save lives, reduce litigation, and lead to improved patient safety,
better health outcomes, and lower overall health-care costs
[8–12].
In Europe, part of the mandate of the Committee for Medici-
nal Products for Human Use (CHMP) is to assess risks and
beneﬁts of authorized medicines on behalf of the European Medi-
cines Agency (EMEA). In 2007, the CHMP revised its guidance
and included quantitative RBA in the regulatory agenda with the
publication of a report examining the potential value of existing
beneﬁt–risk models and methods [13,14]. Although no speciﬁc
method was recommended, several RBA features were noted as
being of value, including 1) all important beneﬁts and medically
serious risks are identiﬁed; and 2) the risks and beneﬁts are
weighted according to their relative importance and the strength
of the evidence available. It was also decided that a comprehen-
sive review of available quantitative methods for RBA relevant to
the CHMP was required to explore further development of tai-
lored methodologies. The EMEA recently created the European
Network of Centres for Pharmacoepidemiology and Pharma-
covigilance, which is in the process of developing an algorithm to
articulate safety and beneﬁt proﬁles for pharmaceutical products.
Regulatory agencies use various methods to discover rare
toxic events. These include review of data from randomized
controlled clinical trials, observational epidemiological studies
(case-control, cohort, and cross-sectional analyses), drug-use
surveys, automated databases linking drugs and disease, sponta-
neous reporting (passive surveillance, such as the FDA’s
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MedWatch program), and established patient registries [15,16].
When a regulatory authority such as the FDA or the EMEA
obtains information about potentially signiﬁcant drug toxicity, it
thoroughly reviews the original new drug application data that
were used for the initial approval. Concurrently, a formal analy-
sis is initiated by reviewing all the spontaneous reports available
from the FDA Adverse Events Reporting System, the United
Kingdom’s Yellow Card Scheme, and the World Health Organi-
zation’s Uppsala Monitoring Centre. Additionally, the sponsor of
a pharmaceutical product is required to review its safety database
and report directly to the regulators. In some circumstances,
further postmarketing studies are designed to answer speciﬁc
questions about toxicity. In the process of reviewing risks and
beneﬁts, a regulatory authority typically seeks input from advi-
sory committees that review safety and efﬁcacy data and make
recommendations [8,9,17]. There is a structured process for con-
vening the appropriate advisory committee. The authority pre-
pares a set of questions involving product safety, efﬁcacy,
study design, results interpretation, and risk–beneﬁt proﬁles
for committee discussion. After review of the advisory commit-
tee’s recommendations, the authority determines a course of
action, which may include changes to labeling, direct correspon-
dence to health professionals, or removal of the drug from the
market.
This traditional process does not produce an explicit, consis-
tent, transparent, and aggregate quantiﬁcation of the risks and
beneﬁts and lacks clarity pertaining to the role of speciﬁc factors
in the recommendations. Although some quantitative measures,
such as quality-adjusted life-years (QALYs) and number needed
to treat (NNT) [11,17–21], discussed later in this article, are used
by regulators, there is lack of standardized and validated quan-
titative methodology. Challenges to developing such a method-
ology include heterogeneity and multiplicity of risks and beneﬁts,
uncertainty regarding attribution of risks and beneﬁts to a par-
ticular treatment, and the temporality and paucity of drug-
exposure and outcome data [18–23]. Furthermore, the
traditional process does not allow for systematic reassessment of
risks and beneﬁts over time. Although an innovative drug may
initially possess advantageous risk–beneﬁt ratios versus older
drugs, these ratios often change over time, as occurred, for
example, with COX-II inhibitors.
Although none of the major regulatory agencies has a clear
benchmark for what constitutes an acceptable level of risk, nev-
ertheless, the pharmaceutical industry is functioning in an era of
increased risk assessment, which requires proactive drug-safety
analysis and additional commitment to safety. Several dozen
risk-management programs or registries have been established by
major pharmaceutical companies in the United States, including
iPLEDGE® to prevent exposure to isotretinoin during preg-
nancy, the clozapine patient registry to prevent agranulocytosis,
an alosetron prescribing program for reducing the risk of severe
gastrointestinal adverse events, and the STEPS® program to
prevent exposure to thalidomide during pregnancy [1–5,24,25].
Moreover, various RBA methods have been utilized for clinical
decision-making in the following drug categories: oral contracep-
tives, antipsychotics, antihyperlipidemia medications, cancer
chemotherapy, iron-chelation, and antihypertensives, among
others [17–19,26–36].
Our study objectives are to review and compare published
quantitative RBA methodologies employed by regulatory agen-
cies and/or the pharmaceutical industry. These comparisons may
help disclose unique characteristics of the RBA techniques that
may be more applicable to a speciﬁc drug evaluation scenario or
a speciﬁc therapeutic indication. This useful information can be
used to inform public and private RBA designers.
Methods
An extensive literature search was ﬁrst performed to identify
qualitative and quantitative approaches to RBA in drug evalua-
tions. The MEDLINE and Cochrane Library databases were used
as well as other Internet-based search engines to ﬁnd scientiﬁc
publications, books, and academic conference proceedings.
Country-speciﬁc drug regulatory Internet Web sites were also
searched. Key words included risk, beneﬁt, risk–beneﬁt assess-
ment, postmarketing surveillance, drug safety surveillance,
adverse drug reactions (ADRs), and pharmacovigilance. Our
inclusion criteria were 1) the publications were in English; and 2)
they focused on pharmaceutical or drug safety surveillance and
provided risk and/or beneﬁt assessment of drugs. Excluded were
conference programs, educational catalogues, announcements in
trade journals, veterinary-medicine publications, animal studies,
ADR case reports, abstracts without speciﬁc information on risk
or beneﬁt assessment, and general discussions related to risk or
beneﬁt assessment for medical devices or biotechnology.
The perspective on RBA was not limited to that of any one
stakeholder. Although both qualitative and quantitative RBA
studies were retrieved from the literature, we reviewed only those
using quantitative methods.
Results
Based on the key words, over 12,000 papers were identiﬁed.
Using our inclusion and exclusion criteria, over 300 abstracts
and Web site summaries related to RBA for drug safety were
identiﬁed and reviewed. Further selection of only quantitative
RBAs resulted in 59 articles, which were used as the basis for this
article. Figure 1 summarizes the process of study selection.
Because of limited published information regarding net clinical
beneﬁt analysis, the principle of threes, and net-beneﬁt-adjusted-
for-utility analysis [10,21,37], we excluded these methods.
Remaining were 12 quantitative RBA methodologies, which are
individually described below and summarized in Table 1. They
are described roughly in chronological order.
Quantitative Framework for Risk–Beneﬁt
Assessment (QFRBA)
Standard notions of risk and beneﬁt are well documented in the
literature as part of a basic quantitative framework (QFRBA).
The QFRBA attempts to quantify these notions directly, and
more recent RBA techniques build on these same ideas.
Risk refers to a comprehensive set of all possible adverse drug
events (ADEs) and a set of probabilities associated with these
adverse outcomes. The basic quantitative expression of risk is the
incidence of adverse events, i.e., the number of new ADEs in a
deﬁned population over a speciﬁc period of time divided by the
population at risk for the adverse event over this same time
period [27,28,38,39]. Relative risk (RR) takes into account dif-
ferences in exposure to the drug and is deﬁned as the ratio
between the proportions of exposed individuals who experience
an ADE divided by the proportion of unexposed individuals who
experience an ADE [38–41]. For example, whereas osteoporotic
individuals are more likely to experience a fracture, there is some
likelihood that people without osteoporosis will fracture as well,
and this fact is accounted for in the RR denominator. Attribut-
able risk (AR), otherwise known as risk difference, uses the same
raw information as in the computation of RR but measures the
absolute difference between the risk of ADEs between those
exposed to the drug and those who were not and then divides this
difference by the absolute difference between the size of the two
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groups [38,40,42]. The population-based attributable risk (PAR)
is an extension of AR that uses total population data. PAR is
particularly important for public-health decision-makers.
The beneﬁt associated with a medication might be its ability
to reduce either an ADE or another adverse event associated with
the disease itself. In this case, relative risk reduction (RRR) is
useful and is deﬁned as the ratio between the proportion of
exposed individuals who experience a decline in adverse events
divided by the proportion of unexposed individuals who experi-
ence such a beneﬁt [27,28,38,40,43]. For instance, again in the
case of osteoporosis, RRR rates are computed for different anti-
osteoporosis medications based on the number of fractures
averted by the treatments. Similarly, attributable risk reducation,
otherwise known as absolute risk reduction (ARR), represents
the decline in adverse events between exposed and unexposed
groups [27,28,38,43]. However, “beneﬁt” does not always mean
absence of adverse events. From clinical trials, beneﬁt measure-
ments might include clinically relevant efﬁcacy parameters such
as speciﬁc biomarkers, surrogates, and putative surrogate end
points [44–46]. From observational studies, beneﬁt measure-
ments could include the patient medication and treatment adher-
ence rate or population-based treatment effectiveness, among
many other possibilities.
The QFBRA methodology is widely used in drug safety sur-
veillance by regulatory agencies and by the pharmaceutical
industry. It has a long history and a solid foundation. The
QFRBA does not, however, provide a methodology for combin-
ing risks and beneﬁts into a single value that could potentially
be used to compare risk–beneﬁt proﬁles between alternative
therapies.
Beneﬁt-Less-Risk Analysis (BLRA)
For BLRA, risk and beneﬁt relationships are presented as risks
subtracted from beneﬁts using weights assigned to one of ﬁve
beneﬁt–risk outcome categories: 1) efﬁcacy without side effects;
2) efﬁcacy with side effects; 3) no efﬁcacy and no side effects; 4)
no efﬁcacy with side effects; and 5) side effects leading to with-
drawal from an ongoing treatment or intolerable side effects
[47,48]. The risk-adjusted beneﬁt measure for each individual is
obtained from the difference between an aggregate beneﬁt score
and an aggregate risk score.
Each patient’s efﬁcacy experience (beneﬁt) of a therapy is
represented by a binary response variable; “1” signiﬁes that a
therapy response is obtained, and “0” means that no response is
achieved. The patient’s side effect experience (risk) from ﬁve
different body functions is represented by a value ranging from
0.0 to 1.0, where the value of 1.0 represents the worst safety
experience and 0.0 means no safety concern. Notably, these
categories are primarily qualitative, but weights can be chosen by
individuals to reﬂect the relative importance of the ﬁve catego-
ries. A mathematical model is derived from these weights and
categories to calculate the observed beneﬁt-less-risk score for an
individual. If applied in a clinical trial comparing different treat-
ments, statistical signiﬁcance tests can be performed to compare
treatments. The interpretation of the results remains focused on
the individual.
The weighting method used is subject to differences in inter-
pretation between individuals. There may be a question regard-
ing the validity of these assessments because the methods used to
present the relative weights may affect the outcome. The conver-
sion from a qualitative assessment into a quantitative value may
also be subject to bias. The advantage of BLRA is that it provides
a structure for combining risks and beneﬁts into a single measure.
Quality-Adjusted Time Without Symptoms and
Toxicity (Q-TWiST)
Another risk–beneﬁt measure is Time Without Symptoms and
Toxicity (TWiST). Time lost due to ADEs or toxicity is sub-
tracted from time gained through treatment. A quality-adjusted
version of TWiST, known as Q-TWiST, converts time into
QALYs; the QALys lost due to ADEs or toxicity are subtracted
from QALys gained from treatment [26,49–51]. The beneﬁt is
measured by drug-attributed gain in QALYs. Cumulative risks of
toxicities and disease progression are calculated to obtain drug-
attributed loss of QALYs (risk). Q-TWiST compares the relative
therapeutic value of treatments based on the patient’s experience
within the context of clinical outcomes related to a disease and its
treatment. This method assumes that patients progress through a
series of health states with varying quality of life. This RBA
method has been used for risk–beneﬁt analysis of cancer treat-
ments [50,52,53], as well as other therapies and transplantation
procedures [54–56]. By weighting the durations of health states
by their respective utility values, a patient arrives at a single end
point reﬂecting the duration of survival and the quality of life.
Using survival analysis techniques, the mean duration of each
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Figure 1 Flowchart of inclusion and exclusion
criteria for identifying published risk–beneﬁt
assessment methods.
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Table 1 Summary of twelve quantitative risk–beneﬁt assessment techniques
Seq. No.
Title and quantitative
approach Parameters for assessment Theoretical model and key features
1 Quantitative Framework for
Risk and Beneﬁt
Assessment (QFRBA)
[27,28,38–40,42–46]
Risk and beneﬁt are deﬁned and quantiﬁed separately;
Risk focuses on adverse events or outcomes, deﬁned as relative
risk, attributable risk, population attributable risk.
Beneﬁt focuses on risk differences (i.e., relative risk reduction,
absolute risk reduction).
Theoretically sound quantitative method;
Probability driven assessment for risk of adverse events and beneﬁts of
improved outcomes;
Relatively simple calculation;
Often used for drug safety surveillance in industry and regulatory
agencies.
2 Beneﬁt-less-risk analysis
(BLRA) [47,48]
Intensity scores are used to compare severity and frequency of
adverse drug events (ADEs) and assigned for each patient.
Data on observed beneﬁt from the treatment are required.
Proportionality constant determines how much penalty the ADEs
offset beneﬁt measure.
Simple empirical method with sound theoretical basis;
Differences between treatments can be statistically analyzed (t-test or
ANOVA);
Requires subjective rankings of ADE intensity scores;
Patient preferences are incorporated using a discounting process;
Subjective ranking for ADEs and proportionality a potential threat to
internal validity;
Useful for comparing one drug treatment to a placebo or alternative
treatment using clinical trial data.
3 Quality-adjusted Time
Without Symptoms and
Toxicity (Q-TWiST)
[49–57]
Beneﬁt measured as drug-attributed gain in quality-adjusted
life-years (QALYs);
Risk measured as drug-attributed loss of QALY
Compare gain versus loss of QALY.
Statistical method can be conducted to compare alternative treatments;
QALYs incorporate patients preference measurement changes over
time;
Validity of QALY measurements and differences between techniques are
potential concerns;
Widely used risk–beneﬁt assessment technique in clinical oncology.
4 Number needed to treat
(NNT) and number
needed to harm (NNH)
[27,28,58–60]
Beneﬁt measure: number of persons treated (NNT) to avoid one
person developing disease of interest (absolute risk reduction,
Relative risk reduction);
Risk measure: number of persons treated when one person
experiences ADE (NNH);
Ratio of NNT and NNH.
Well-deﬁned quantitative framework;
Simple calculation for RBA used for comparing treatment and control
groups;
Lack of strong statistical properties;
Risk–beneﬁt relation can be compared directly by NNT to NNH ratio;
NNT should be lower than NNH for the drug to be valuable in term of
risk beneﬁt ratio;
Widely used for RBA in different therapy areas;
Difﬁcult to incorporate more than one outcome (ADE or beneﬁt
reduction) simultaneously;
Relative value of ADE versus beneﬁt not considered.
5 Relative value adjusted
number needed to treat
(RV-NNT) [27,28]
Expands NNT to incorporate relative utility values (RV) based upon
patient preferences;
RV-NNH can be also be determined;
Ratio of RV-NNT and RV-NNH.
Well-deﬁned quantitative framework with relatively simple calculation;
RV measures involve patient’s preference for speciﬁc ADEs or avoidance
of negative clinical outcomes;
Similarly to NNT/NNH ratio, the RV-NNT must be higher than the
RV-NNH for the drug to be valuable.
6 Minimum clinical efﬁcacy
(MCE) [27,28,61]
Beneﬁt stated as efﬁcacy difference between new treatment and
conventional treatment or placebo;
Harm stated as probability of AE (risk) in patients receiving new
treatment vs. conventional treatment or placebo;
Relative utility values may be considered.
Quantitative framework for integrating risk–beneﬁt data into a single
decision rule;
New treatment is warranted over conventional treatment if efﬁcacy
exceeds probability of AE;
More than one type of AEs can be considered;
Lack of strong statistical properties;
Does not incorporate uncertainty in the beneﬁt or risk measurements;
Applied primarily for cardiovascular treatments.
7 Incremental net health
beneﬁt (INHB) [17,62]
Risk measured as decrease in QALY;
Beneﬁt measured as improvement in QALY;
INHB as relative gain or loss of QALYs due to treatment versus
usual care or placebo.
Theoretically sound modeling method;
Risk–beneﬁt relation presented as an incremental difference;
QALY data from clinical trials are required;
Statistical variance in the estimates of both risks and beneﬁts can be
calculated;
Potential application in clinical and regulatory decision-making.
8 Risk–beneﬁt plane (RBP) and
risk–beneﬁt acceptability
threshold (RBAT) [18,64]
Risk measured as relative probability of risk of AEs between
treatment and control groups;
Beneﬁt measured as relative probability response between
treatment and control groups;
Visual application of risk–beneﬁt comparisons.
Well-deﬁned theoretical model;
Two-dimensional plot with beneﬁt measurement on x-axis, risk
measurement on y-axis;
An acceptable threshold of relative risk–beneﬁt ratio can be plotted to
visually compare with other treatments;
Often used for explaining the phenomenon of drug safety surveillance.
9 Probabilistic simulation
methods (PSM) and
Monte Carlo simulation
(MCS) [18,62–64]
Average difference in the probability of risk and beneﬁt for the new
therapy relative to conventional therapy;
Incremental risk–beneﬁt ratio (IRBR).
Framework applies incremental risk–beneﬁt ratio;
Joint density of beneﬁt and risk scatter plot can be presented with a
risk–beneﬁt acceptability curve;
Involves simulation modeling of uncertainty around the incremental
risk–beneﬁt differences;
Statistical support incorporated using nonparametric bootstrap method
and MCS.
10 Multicriteria decision analysis
(MCDA) [45,46]
Beneﬁt measured as clinically relevant end points from clinical trials;
Risk measured as incidence of ADE, discontinuation rate, drug
interactions, and other risk criteria;
Decision tree model is developed to incorporate all key risks and
beneﬁts;
Relative weights are of risks and beneﬁts are assigned.
A decision tree describes clinical outcomes in a hierarchical manner;
Decision-making tool incorporates evaluation of both drug’s risks and
beneﬁts;
Relative scores for alternative treatments can be calculated based on
modeling;
Data extraction from clinical trials are critical for internal validity;
Missing data and uncertainty can be addressed.
Implication for clinical and regulatory policy decision makings.
11 Risk–beneﬁt Contour (RBC)
[66]
Probability of potential beneﬁt of treatment such as an increased
survival rate;
Probability of potential risk due to severe ADE or drug toxicity.
Graphical depiction of both beneﬁt (x-axis) and risk (y-axis)
measurements on a two-dimensional graph;
Risk–beneﬁt contours for comparative treatments are plotted as a set of
nonlinear curves;
For each individual patient, RBC scores can be identiﬁed with conﬁdence
intervals;
Useful tool for clinical making decisions.
12 Stated preference method
(SPM) or maximum
acceptable risk (MAR)
[67–77]
Relative utility values for therapeutic treatment alternatives;
Vector of attribute levels for treatment options;
Beneﬁt–risk trade-off preferences estimated by probability of severe
AEs versus beneﬁt in terms of treatment success;
Patient surveys required to provide data regarding value of beneﬁt
versus negative impact of risk.
SPM/MAR is based on hedonic-utility principles, and uses similar
techniques to contingent valuation;
Patient’s preferences for beneﬁt–risk trade-offs are incorporated.
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disease state and the mean quality-adjusted survival time can be
estimated [52–57].
As for BLRA, Q-TWiST provides a summary measure incor-
porating both beneﬁts and risks over time. Quality-adjusted sur-
vival is an understandable concept and can help individual
patients make informed treatment decisions. As with any QALY-
based methodology, concerns regarding the validity and applica-
tion of QALYs in a broad decision-making context are inherent
with the method. Additionally, the type of QALY-measurement
technique may inﬂuence the results.
NNT and Number Needed to Harm (NNH)
NNT is deﬁned as the number of patients who need to be treated
in order to prevent one more occurrence of a disease
[27,28,39,58–60]. NNT can be calculated by taking the recipro-
cal of the ARR, and, as such, is dependent upon the incidence of
the disease for calculating ARR. Treatment is warranted if NNT
is low enough so that beneﬁts accrue at a sufﬁciently low number
of patients before ADEs occur [27,28,58–60].
NNH is calculated similarly for ADEs related to a speciﬁc
therapy, thus describing how many patients will be treated before
a patient will experience an ADE [27,28,58–60]. Both NNT and
NNH have been used widely for RBA across different therapeutic
areas [29,30,33,34,58,59]. A comparison between NNT and
NNH can be used as a very basic comparison of beneﬁt versus
risk for a population of patients who may beneﬁt from the
treatment. Indeed, a risk–beneﬁt ratio equal to NNH/NNT can
be calculated between treatment and control groups. If the ratio
is greater than 1 (i.e., NNH/NNT > 1 or NNT < NNH), then
fewer patients need to be treated to achieve beneﬁt than will be
treated to have one additional occurrence of an ADE [27,28].
Rather than compare NNT and NNH explicitly, NNT can be
adjusted to account for ADE potential. Adverse-event-adjusted
NNT is deﬁned as the number of patients who need to be treated
to prevent one additional disease outcome after adjusting for the
potential risks (e.g., ADEs) of the treatment, that is, after allow-
ing for the probability of incurring a treatment-related adverse
event [27,28].
Both NNT and NNH are widely used in clinical practice
because they are simple decision-making tools for clinicians.
Indeed, these tools currently have a ubiquitous role in medical
decision-making. However, NNT and NNH by themselves do
not account for the patients’ value of the beneﬁt or the value of
the harm, respectively. In addition, it is cognitively complex to
incorporate several beneﬁts and harms simultaneously, which
commonly exists in clinical situations.
Relative-Value-Adjusted- (RV) NNT and RV-NNH
In an attempt to account for patient preferences, both the NNT
and NNH measures have been revised to incorporate patients’
relative utility values, in this way correcting for one of the prob-
lems mentioned above. Adding a patient’s relative utility values
to the risk–beneﬁt evaluation should make this RBA method
more robust [27,28]. Relative utility values are obtained using
either the standard-gamble method or the time-trade-off
approach. A metric, RV, is calculated from a numeric represen-
tation of patients’ preferences for speciﬁc outcomes. Speciﬁcally,
RV = (1 - utility of adverse event)/(utility of improvement using
a speciﬁc treatment), where the value of 1 represents the value of
perfect health. RV can then be interpreted as a quantiﬁcation of
the overall value of patients’ preferences for avoiding an ADE
relative to avoiding the disease of interest or target event.
NNH adjusted for relative value can also be calculated simi-
larly to RV-NNT. Thus, a risk–beneﬁt ratio (RV-NNH/NNT) can
be also calculated between treatment and control comparison
groups. A favorable risk–beneﬁt outcome is obtained when
RV-NNH/NNT > 1. This technique overcomes one of the weak-
nesses of NNH and NNT. It may also be possible to incorporate
several beneﬁts and risks simultaneously using this technique.
Minimum Clinical Efﬁcacy (MCE)
The MCE of a treatment is deﬁned as the minimal clinical efﬁcacy
required by the treatment in comparison with a standard treat-
ment, after taking into account the efﬁcacy of the standard treat-
ment, the adverse event proﬁles associated with both the
standard treatment and the treatment under consideration, and
the risk of the disease of interest associated with no treatment
[27,28,61]. A broader deﬁnition of beneﬁt as the efﬁcacy differ-
ence between two treatments (the new treatment versus the stan-
dard treatment) is calculated for RRR for the disease of interest.
Risk of an adverse event among persons treated with the new
treatment versus the standard treatment can also be calculated
[27,28,61]. A new treatment is warranted over the standard
treatment if the difference in risk is less than the efﬁcacy differ-
ence. MCE seeks to improve clinical care through a quantitative
comparison of the potential beneﬁt against the potential risk of a
particular treatment. MCE takes into account not only the ben-
eﬁts and harms of the new and standard treatments but also the
natural characteristics of the disease in the general population,
represented by an untreated group.
The MCE method seeks to ﬁnd the minimal therapeutic
beneﬁt at which a treatment is worth administering, which can be
used as a yardstick for the acceptance of a new treatment alter-
native. The details required to balance the ADE proﬁles as well as
efﬁcacy impact can be extensive. This method is similar to the
RV-NNT model [27,28], which cannot easily handle uncertainty
in the measurement of beneﬁts or risks.
Incremental Net Health Beneﬁt (INHB)
Risk–beneﬁt differentials can be expressed as either ratios or
differences, although the latter are more mathematically manage-
able if the units of measurement are the same. The INHB accom-
plishes this through the application of QALYs. The INHB of a
treatment in comparison with standard treatments is calculated
as the incremental difference between effectiveness and risk
changes; i.e., INHB = (E2 - E1) - (R2 - R1), where E denotes
effectiveness, and R is risk [17]. Both risk and beneﬁt must be
measured using QALYs. A favorable risk–beneﬁt balance exists
when (E2 - E1) > (R2 - R1). That is, the expected QALY gains as
a result of efﬁcacy must exceed the expected losses from risk
(ADEs) in order for the net health beneﬁt to be positive [17,62].
Some of the literature mentioned that the beneﬁts and risks for
INHB could be measured using value-adjusted life-years as
opposed to QALYs [63].
The INHB approach is a theoretically sound modeling
method with strong potential for usefulness in clinical and regu-
latory decision-making. As with Q-TWiST, the potential prob-
lems with this technique rely upon the inherent difﬁculties with
the use of QALYs as outcome measures. Furthermore, these
measurements must be accrued over time to gather sufﬁcient
data. There may be beneﬁts or risks that occur after the time of
original data collection.
Risk–Beneﬁt Plane (RBP) and Risk–Beneﬁt Acceptability
Threshold (RBAT)
For this method, the beneﬁt–risk ratio can be interpreted as the
increase in the expected number of patients who will beneﬁt for
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each additional ADE that occurs—from new treatment rather
than usual care [64]. R = (PE - PC)/(qE - qC), where the probabili-
ties of beneﬁt from the experimental treatment and in the control
arm are PE and PC, respectively, and the probabilities of risk from
the experimental treatment and in the control arm are qE and qC,
respectively [17,63].
Figure 2 shows a hypothetical model of the RBP, which is a
two-dimensional plot with beneﬁt and risk on the two axes,
including four quadrants NE, SE, NW, and SW [17,64]. The risk
measurement can be incidence of ADEs or frequency of ADE. If
the risk is on the x-axis, the risk for the new therapy increases
from left to right. The beneﬁt measurement can be incidence of
beneﬁt or product of efﬁcacy and responder rate. The beneﬁt on
the y-axis increases from bottom to top. Hence, risk–beneﬁt
ratios in NW depicts that experimental therapy dominates
because of this treatment option with low risk and high beneﬁt.
In the SE quadrant, the active treatment option has higher risks
and lower beneﬁts (with a high risk–beneﬁt ratio), and the
control therapy is said to dominate. The remaining two quad-
rants involve high risk and more beneﬁt in SW, and less risk and
less beneﬁt in NE. An appropriate risk–beneﬁtRBAT will be
determined in RBP plot, which is indicated by a slope of line that
crosses over the SW and NE quadrants [15,62].
This method is a well-deﬁned hypothetical model and offers a
visual tool to make complex comparisons between risk and
beneﬁt. Some ambiguity is associated with collapsing beneﬁts
and risks into single measures. Because of two-dimensional
model for RBP, it is unclear how one might incorporate multiple
dimensions of risks and beneﬁts. It may be useful to use these
types of graphical representations in patient decision-making
regarding alternative treatments.
Probabilistic Simulation Methods (PSMs) and Monte
Carlo Simulation (MCS)
Similar to the above RBP model, the average difference in the
probability of achieving a beneﬁt with the new therapy relative to
conventional therapy can be plotted on the x-axis (DB), and the
average difference in the probability of risk for the new therapy
can be plotted on the y-axis (DR). Both axes therefore range from
-1 to 1, with 0 at the origin. Then, four quadrants are labeled
with points of the compass NE, SE, NW, and SW [17,62,64].
Because the beneﬁt increases from left to right along the x-axis,
positive values (to the right of the vertical axis) represent greater
beneﬁts with the new treatment. Similarly, positive Y-coordinates
indicate a greater probability of the risk for the new treatment.
Figure 3 demonstrates a hypothetical model of PSM. Using
differences in the probability of achieving beneﬁt and risk, the
incremental risk–beneﬁt ratio related to the new therapy can be
deﬁned as the incremental probability of an ADE (DR) with a
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Figure 2 Hypothetical model for risk–beneﬁt
plan and acceptable risk–beneﬁt threshold for
risk–beneﬁt assessment. Revised ﬁgure from
Shaffer et al. [64] BMC Med Res Methodology
2006;6:48.
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new therapy relative to conventional treatment divided by the
incremental probability of a beneﬁcial effect (DB) [18]. The y-axis
represents average difference in the probability of risk for the
new therapy versus conventional treatment.
There are two potential methods for quantifying the joint
density of the uncertainty around the risks and beneﬁts, depend-
ing on the accessibility of patient-level data [18]. If data are
available, a nonparametric bootstrap sample of data can be
selected repeatedly; if original data are not available, a simula-
tion can be run using information on the distributions ﬁt to the
data. From the simulations or bootstrap estimates, the incremen-
tal risk–beneﬁt pairs can be plotted on the RBPrisk–beneﬁt. For
example, in a randomized, double-blind, controlled clinical trial,
low-dose unfractionated heparin was compared with a low
molecular weight heparin, enoxaparin, for the prophylaxis of
venous thromboembolism following major trauma [65]. In a
previous clinical study, a MCS was applied to compare the efﬁ-
cacy and safety of administering anticoagulants to trauma
patients who are already at an elevated risk of bleeding [18].
RBP permits the estimation of the joint density of risks and
beneﬁts with their associated uncertainty and facilitates estima-
tion of the probability that a therapy is net-beneﬁcial. MCS can
be used to compare drugs for both efﬁcacy and safety. These tools
rely upon more complex statistical techniques to describe rela-
tionships between treatments similar to RBP. The same limita-
tions exist, but the statistical modeling provides a greater level of
conﬁdence in the ﬁndings, and provides the data used to generate
the results are valid and are collected reliably.
Multicriteria Decision Analysis (MCDA)
MCDA is a decision tool aimed at supporting decision-makers
who are faced with making numerous risk and beneﬁt evalua-
tions. The risk can be measured by incidence of ADEs, discon-
tinuation rate due to ADEs, and other risk factors such as
potential drug interactions, off-label use leading to safety
hazards, and safety issues observed in preclinical safety studies
[45,46]. The beneﬁt involves clinically relevant end points from
clinical trials and other beneﬁt criteria.
Using a decision value tree, a risk–beneﬁt ratio for a speciﬁc
drug therapy can be evaluated systematically. Both beneﬁt and
risk criteria can be split into multiple criteria in case of different
primary end points, relevant subgroups, and relevant interactions
[45,46]. Beneﬁt criteria can be split into one or more pivotal
trials and other beneﬁt criteria. Each pivotal trial may include
efﬁcacy related to primary end points in overall subjects and in
relevant subgroups, as well as efﬁcacy nonprimary end points.
Other beneﬁt criteria may include efﬁcacy from nonpivotal trials
and anticipated patient compliance in clinical practice. Risk cri-
teria are split into adverse effects, other risk criteria, and poten-
tial for nondemonstrated additional risks. Each adverse effect
involves its incidence and discontinuation rate. Other risk criteria
involve safety in subgroups, interaction with other drugs and
food, and potential for off-label use leading to safety hazards.
Potential for nondemonstrated additional risk involves long-term
exposure safety proﬁle, safety issues observed in preclinical
studies, and safety issues observed in the same pharmacological
class [45,46].
MCDA can handle missing data and uncertainty using appro-
priate modeling and relative weights. There are several key steps
for MCDA. First, the decision context (tree) needs to be estab-
lished with deﬁned options. Clear objectives and criteria should
be identiﬁed for assessing the consequences for each option with
high-level and low-level rates of occurrence in the hierarchy.
Then, the expected performance scores of each option against the
criteria of consequences should be assessed. Finally, weighted
scores at each level in the hierarchy and overall weighted scores
can be calculated. The result can be examined with sensitivity
analysis [45,46].
MCDA is a relatively new model that takes in account mul-
tiple criteria, judgment, and uncertainty. Although the MCDA
model can be customized by adding or changing beneﬁt and risk
criteria, the process may be too burdensome for limited evalua-
tions. Data extraction from clinical trials is critical for the inter-
nal validity assessment of the MCDA technique.
Risk–Beneﬁt Contour (RBC)
The RBC is another relatively new method that provides a two-
dimensional graph showing both the probability of beneﬁt from
treatment based, for example, on the survival rate and the prob-
ability of drug toxicity or ADEs (the risk) [66]. The degree of
drug beneﬁt is captured along the x-axis, and the degree of drug
risk is measured along the y-axis. By ﬁnding out from each
patient the amount of risk he or she is willing to accept to obtain
a certain beneﬁt, a set of individual RBCrisk–beneﬁts can be
determined. For example, the RBC can show whether a patient is
willing to accept a 40% probability of acute toxicity as long as
there is a 5% improvement in the chance of survival [66].
The RBC approach is a way of formalizing the risk–beneﬁt
trade-off for patients and, as such, can be a useful tool for
patients and physicians. It can take information from clinical
trials in order to present the risk–beneﬁt trade-off visually.
However, as unique to each patient, the, RBC method does not
have an intrinsic risk–beneﬁt threshold and does not allow for
multiple risks and multiple beneﬁts from a drug therapy.
Stated Preference Method (SPM) or Maximum
Acceptable Risk (MAR)
SPM or MAR is based on hedonic-utility principles and thera-
peutic treatment options (commodities) over which consumers
make choices. Consumer choices can be considered as a random
utility function speciﬁed as Uj = Vj + ej with Vj = Xjb [67], where
Vj is the determinate part of the utility function for treatment j,
Xj is a vector of attribute levels for treatment j, b is a vector of
attribute parameters, and ej is a random error. Beneﬁt–risk trade-
off preferences can be estimated based on consumer experience
or probability of adverse events (AEs). Patients’ preferences can
be collected from survey questionnaires and interview techniques
such as contingent valuation techniques. The current best prac-
tice standard requires participants to make trade-offs between
choices using discrete choice experiments. Best–worst scaling
methods are also being developed and may become more wisely
used in the future. Using SPM or MAR, the risk–beneﬁt trade-off
can be calculated as the increase in risk of AEs that reduces the
patients’ satisfaction scores between two treatment options. This
RBA method has been applied to several therapeutic areas such
as Crohn, HIV, type 2 diabetes, multiple sclerosis treatments, and
vasomotor symptom relief [68–77].
SPM or MAR is theoretically sound and uses similar tech-
niques to contingent valuation. It requires the collection of
patients’ treatment preference, which allows the evaluation of
beneﬁt–risk trade-offs. The method can demonstrate the patient’s
willingness to accept risks to the beneﬁts of controlling disease
symptoms.
Discussion
Multiple scientiﬁc methods that quantify beneﬁts and risks of
medical treatments are available and can be used to reduce the
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current subjective onus on regulatory agencies, thus guiding them
to more objective and transparent decisions regarding drug efﬁ-
cacy and safety. Each assessment method requires different data
and has its unique characteristics and features, as well as
strengths and weaknesses. The reviewed methodologies for RBA
are representative of technical advances in the ﬁeld of quantita-
tive analysis. So far, they have been used primarily for research
demonstrations and to showcase their scientiﬁc and mathemati-
cal feasibility. They have not yet been systematically adopted by
regulatory agencies or by the pharmaceutical industry. The
reviewed RBA methods might be helpful for making decisions at
the population level. In addition, they are clearly valuable in
providing information for individual patients and their physi-
cians in disease treatment decisions.
In trying to develop a consistent RBA strategy, Lynd (Lynd L,
unpublished presentation) suggested that desirable features
include 1) universal applicability across medications; 2) inclu-
siveness (taking account of all risks and beneﬁts); 3) patient
sensitivity (person-speciﬁc preference weightings); 4) straightfor-
ward interpretability; 5) ﬂexibility; 6) adaptability; 7) ability to
incorporate uncertainty; 8) integrability with economic evalua-
tions of medications; and 9) ability to be consistent with a
quantitative risk–beneﬁt threshold. Some methods like INHB,
RBP, PSM, MCDA, SPM, and RBC seem to be ﬂexible and easier
to adopt for certain clinical situations than others. Although
some have argued that INHB is the best RBA because it meets all
nine criteria, it is too early to conclude that any single method is
suitable for all purposes [2,8–10,21,66,78]. From ongoing aca-
demic activities at both the FDA and the EMEA, three RBA
approaches have received the most attention: INHB using health-
outcomes modeling, MCDA, and SPM (comments from an
expert reviewer which is based on communication with the FDA
and the EMEA).
Because RBP and PSM provide health-care decision-makers
with a functional relationship between patient preference and
probability of net beneﬁt, they may be two promising methods
for forming a standardized approach to modeling risk–beneﬁt
relationships. Signiﬁcant research, however, is required to deter-
mine probability distributions for incremental risks and beneﬁts.
Further validation using multiple data sets and various simula-
tion techniques may be required to generate comparative results.
On the other hand, BLRA may be most appropriate for compari-
sons between treatments in the same therapeutic class because it
takes both beneﬁt and risk into consideration as long as the risks
and beneﬁts are available in similar qualitative measurements.
Nevertheless, BLRA does not clearly delineate beneﬁt and risk,
and interpretation is very complicated.
We note that both RV-NNT and MCE analysis rely heavily
upon efﬁcacy or effectiveness data, adverse event rates, and
patient preference (utility) data. Patients must specify their rela-
tive preferences for an outcome given potential risks. These data
may be difﬁcult to obtain. Furthermore, NNT has been criticized
for its lack of strong statistical properties. When the ARR value
gets closer to 0, NNT will be nearly inﬁnity and therefore hard to
interpret [27,28]. MCE analysis allows for determining the
worth of a new treatment relative to an older one, given not only
the potential risks of adverse events and beneﬁts that may be
gained, but also taking into account the risk of disease without
any treatment. However, statistical properties for MCE are
unstudied, and it is not clear whether a valid conﬁdence interval
can be created around an MCE value [27,28].
The QALY is often used to measure disease burden and
provides the foundation for cost-effectiveness analysis despite the
difﬁculties in measuring QALYs lost or gained through adverse
events or successful therapy, respectively. QALYs are used for
both INHB and Q-TWiST; beneﬁt is measured by expected
health improvements (QALY gains), whereas risk is measured by
adverse health impacts (QALY losses). QALY estimates for
known potential side effects may be inferred from knowledge of
the product’s mechanism of action or signals from clinical trials.
Information about rare events may be nonexistent when a drug is
ﬁrst marketed before wider exposure to the drug by patients.
Presumably, one could rely on broad historical experience in
order to include an explicit but very small probability for a rare
event [17,62]. In the absence of obtainable utilities from the
literature or other studies, primary data collection may be
required to determine these values.
We are not suggesting that any or all of the quantitative RBA
approaches reviewed here should replace the existing decision-
making process of either clinicians or regulatory agencies; rather,
they should serve as supplemental tools to inform such decision-
making. Quantitative RBA methodologies may be particularly
beneﬁcial in an era of limited health-care resources for making
appropriate decisions about pharmaceutical products. All
reviewed RBA methods have limitations, predominantly in their
data requirements, statistical properties, and the availability of
valid patient preference measures (utilities). In many situations,
we are limited to retrospective analysis of historical data and
existing databases.
Limitations and Future Research
The present study was limited to review of existing, published
scientiﬁc RBA techniques by using a Web-based literature review
of peer-reviewed journal articles found through PubMed/
MEDLINE, the Cochrane Library, the FDA repository, and
other Internet-based search engines. Many other risk–beneﬁt
approaches based on speciﬁc clinical parameters or speciﬁc per-
spectives were not included [79–84]. There may also be other
quantitative approaches that regulators have not formalized or
published. Further research is warranted to ensure the robustness
of these latter measures and to deﬁne the appropriate context in
which they should be applied. Our review of RBA methods is
consistent with the observation that technical development of
risk–beneﬁt analysis is far from what is needed in the con-
temporary regulatory environment of pharmaceutical product
development.
Conclusion
Several scientiﬁcally sound, quantitative RBA methodologies can
be used to reduce the current subjective onus on the regulatory
agencies and help guide them toward making more objective,
transparent, and evidenced-based decisions regarding drug risks
and beneﬁts. Each quantitative method has its unique advantages
and disadvantages based on data requirements and statistical
properties. Whereas some methods rely on subjective weighting
schemes or simple statistical assessments (e.g., NNT and NNH),
other methods are used for obtaining joint distributions of
beneﬁt and risk (e.g., RBP, PSM, MCDA, SPM, and RBC) and
have a sound mathematical basis. Methods that incorporate the
patient’s risk tolerance and preference for health states may
represent a promising channel of study in this area. Numerous
RBA methodologies have been proposed, but there are a limited
number of empirical applications of these techniques, and there is
no consensus among regulators necessary for deﬁning a clear
gold standard. More testing, and particularly head-to-head com-
parisons, is needed if these approaches are to receive serious
consideration. When evaluating any new health-care technology,
we recommend the use of multiple RBA approaches across
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different therapeutic indications and treatment populations to
bound the risk–beneﬁt proﬁle.
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